Nocebo in headaches: Implications for clinical practice and trial design

Current Neurology and Neuroscience Reports

Volumn 12, Issue 2, 2012, Pages 132-137

  Mitsikostas, Dimos D ^a  

^a ATHENS NAVAL HOSPITAL   (Greece)

Author keywords

Adverse events; Migraine; Nocebo; Placebo; Tension type headache; Treatment; Trial design

Indexed keywords

ANTICONVULSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TRIPTAN DERIVATIVE;

ARTICLE; CLINICAL PRACTICE; CLUSTER HEADACHE; DISEASE SEVERITY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FIBROMYALGIA; HUMAN; IATROGENIC DISEASE; META ANALYSIS (TOPIC); METHODOLOGY; MIGRAINE; MULTIPLE SCLEROSIS; NEUROPATHIC PAIN; NOCEBO; PARKINSON DISEASE; PRIMARY HEADACHE; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STUDY DESIGN; TENSION HEADACHE; TREATMENT DURATION; TREATMENT REFUSAL;

ANTICIPATION, PSYCHOLOGICAL; HUMANS; META-ANALYSIS AS TOPIC; MIGRAINE DISORDERS; PATIENT DROPOUTS; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TENSION-TYPE HEADACHE;

EID: 84861227303     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-011-0245-4     Document Type: Article

References (36)

1. Kennedy WP. The nocebo reaction. Med World. 1961;95:203-5.
2. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA. 2002;287:622-7. (Pubitemid 34252015)
3. Enck P, Benedetti F, Schedlowski M. New insights into the placebo and nocebo responses. Neuron. 2008;59:195-206. (Pubitemid 352033692)
4. Papadopoulos D, Mitsikostas DD. Nocebo effects in multiple sclerosis trials: a meta-analysis. Mult Scler. 2010;16:816-28.
5. van Laarhoven AI, Vogelaar ML, Wilder-Smith OH, et al. Induction of nocebo and placebo effects on itch and pain by verbal suggestions. Pain. 2011;152:1486-94. Epub 2011 Feb 24.
6. Varelmann D, Pancaro C, Cappiello EC, Camann WR. Noceboinduced hyperalgesia during local anesthetic injection. Anesth Analg. 2010;110:868-70.
7. Colloca L, Sigaudo M, Benedetti F. The role of learning in nocebo and placebo effects. Pain. 2008;136:211-8.
8. Benedetti F, Lanotte M, Lopiano L, Colloca L. When words are painful: unraveling the mechanisms of the nocebo effect. Neuroscience. 2007 29;147:260-71. (Pubitemid 46907442)
9. Vase L, Robinson ME, Verne GN, Price DD. The contributions of suggestion, desire, and expectation to placebo effects in irritable bowel syndrome patients. An empirical investigation. Pain. 2003;105:17-25. (Pubitemid 37162469)
10. Benedetti F, Amanzio M. The placebo response: How words and rituals change the patient's brain. Patient Educ Couns. 2011;84:413-9.
11. Benedetti F, Amanzio M. The neurobiology of placebo analgesia: from endogenous opioids to cholecystokinin. Prog Neurobiol. 1997;52:109-25. (Pubitemid 27242702)
12. Benedetti F, Amanzio M, Casadio C, et al. Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide. Pain. 1997;71:135-40. (Pubitemid 27232422)
13. Benedetti F, Amanzio M, Vighetti S, Asteggiano G. The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect. J Neurosci. 2006;26:12014-22. (Pubitemid 44772112)
14. Kong J, Gollub RL, Polich G, et al. A functional magnetic resonance imaging study on the neural mechanisms of hyperalgesic nocebo effect. J Neurosci. 2008;28:13354-62.
15. Scott DJ, Stohler CS, Egnatuk CM, et al. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry. 2008;65:220-31. (Pubitemid 351214321)
16. Tracey I. Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans. Nat Med. 2010;16:1277-83.
17. Evans WR. Headaches and the nocebo effect. Headache. 2003;43:1111-5.
18. Colloca L, Miller FG. The nocebo effect and its relevance for clinical practice. Psychosom Med. 2011 Aug 23. [Epub ahead of print]
19. Merikangas KR, Cui L, Richardson AK, et al. Magnitude, impact, and stability of primary headache subtypes: 30 year prospective Swiss cohort study. BMJ. 2011;343:d5076.
20. Lipton RB. Chronic migraine, classification, differential diagnosis, and epidemiology. Headache. 2011;51 Suppl 2:77-83.
21. Reuter U, Sanchez del Rio M, Carpay JA, et al. GSK headache masters program: placebo adverse events in headache trials: headache as an adverse event of placebo. Cephalalgia. 2003;23:496-503. (Pubitemid 37114970)
22. Loder E, Goldstein R, Biondi D. Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls. Cephalalgia. 2004;25:124-31. (Pubitemid 40193955)
23. Amanzion M, Corazzini LL, Vase L, Benedetti F. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain 2009; 146: 261-269.
24. Mitsikostas DD, Mantonakis LI, Chalarakis NG. Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches. Cephalalgia 2011;31:550-61.
25. Amanzio M. Do we need a new procedure for the assessment of adverse events in anti-migraine clinical trials? Recent Pat CNS Drug Discov. 2011;6:41-7.
26. Dodick DW, Turkel CC, DeGryse RE, et al. PREEMPT Chronic Migraine Study Group: OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPTclinical program. Headache. 2010;50:921-36.
27. Manzoni GC, Torelli P. Epidemiological classification and social impact of chronic headache. Intern Emerg Med. 2010;5 Suppl 1: S1-5.
28. Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight project. J Headache Pain. 2010;11:289-99.
29. Papadopoulos D, Mitsikostas DD. A meta-analytic approach to estimating nocebo effects in neuropathic pain trials. J Neurol. 2011 Aug 3. [Epub ahead of print].
30. Mitsikostas DD, Chalarakis NG, Mantonakis LI, et al. Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for practice. Eur J Neurol 2011 Oct 4. doi:10.1111/j.1468-1331. 2011.03528.x.
31. de la Cruz M, Hui D, Parsons HA, Bruera E. Placebo and nocebo effects in randomized double-blind clinical trials of agents for the therapy for fatigue in patients with advanced cancer. Cancer. 2010;116:766-74.
32. Price DD, Craggs JG, Zhou Q, et al. Widespread hyperalgesia in irritable bowel syndrome is dynamically maintained by tonic visceral impulse input and placebo/nocebo factors: evidence from human psychophysics, animal models, and neuroimaging. Neuro- Image. 2009;47:995-1001.
33. Grimes DA, Schulz KF. Nonspecific side effects of oral contraceptives: nocebo or noise? Contraception. 2011;83:5-9.
34. Weissenfeld J, Stock S, Lüngen M, Gerber A. The nocebo effect: a reason for patients' non-adherence to generic substitution? Pharmazie. 2010;65:451-6.
35. Vernia P, Di Camillo M, Foglietta T, et al. Diagnosis of lactose intolerance and the "nocebo" effect: the role of negative expectations. Dig Liver Dis. 2010;42:616-9.
36. Haga SB, Warner LR, O'Daniel J. The potential of a placebo/nocebo effect in pharmacogenetics. Public Health Genomics. 2009;12:158-62.